Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia

SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials.

The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore's public healthcare system.

Curie Oncology: using AI to bring more trials to patients

Curie Oncology currently runs numerous clinical trials across Singapore and Malaysia. As the group expands its research footprint, the volume of data required to identify eligible patients has increased significantly.

Digitalisation in healthcare has generated large volumes of data with valuable clinical insights. This information ranges from structured datasets like lab results to unstructured content such as free-text notes created inside and outside clinical environments. Yet over 80% of health data is unstructured, making it difficult for research teams to process efficiently or consistently. These limitations create significant barriers for researchers who need reliable, analysis-ready information.

Through the partnership, Curie Oncology is now using Oncoshot's AI tools to rapidly structure and analyse clinical data, enabling its oncologists and research teams to identify eligible patients sooner and offer access to ongoing trials more efficiently.

"Oncoshot helped us restructure our rich clinical and genomic data. We can now use natural language to query this information, enabling us to match patients to innovative therapies, improve patient outcomes, and perform cost-benefit analysis," said Dr Toh Chee Keong, medical oncologist and head of research at Curie Oncology.

AI as an enabler: Oncoshot's role in supporting Curie's research teams

Oncoshot's platform functions as a secure, behind-the-scenes engine that converts unstructured oncology documents into research-ready datasets. During Curie Oncology's rollout, the AI system:

• Extracted and de-identified data with over 95% accuracy, even across varied source systems
• Allowed research coordinators to spend more time on patient-facing and trial-critical tasks, instead of repetitive data processing

Oncoshot's role is to support, not replace, Curie's clinical research processes. The AI system helps teams screen faster, run feasibility checks more consistently, and scale their research programmes without requiring proportional increases in manpower.

"Our focus is to enable clinicians and research staff to do what they do best: care for patients and run high-quality clinical studies," said Dr Huren Sivaraj, CEO and head of clinical AI at Oncoshot. "AI simply removes the manual bottlenecks that make oncology research and access to innovative trials so resource intensive."

Public and private sector adoption

Curie Oncology is among the first private oncology networks in Asia to deploy Oncoshot's AI platform, extending the company's work with earlier public-facing collaborations across Singapore's cancer research ecosystem.

This includes earlier collaborations such as the 2022 project with Icon Cancer Centre and Roche to digitise genomic data, a workflow that has since been fully automated, as well as deployments with Tan Tock Seng Hospital and the National Cancer Centre Singapore which were highlighted in presentations at the International Association of Cancer Registries (IACR) 2025.

Together, these implementations illustrate how AI can support both public and private cancer institutions in processing unstructured oncology data securely and efficiently. Oncoshot's federated architecture ensures that raw patient data remains within each institution's environment, while maintaining compliance with HIPAA, GDPR, and Singapore PDPC regulations.

About Curie Oncology

Curie Oncology is a multi-site regional oncology group operating across Singapore, Malaysia, and the Philippines, with active collaborations in Indonesia and Vietnam. With a strong emphasis on clinical research, Curie runs numerous ongoing studies, providing patients with access to new therapies and precision oncology approaches.

About Oncoshot

Oncoshot is an oncology-focused AI company that helps hospitals and cancer centres transform unstructured clinical data into secure, analysis-ready datasets. Its in-premise medical LLM and federated architecture reduce friction in data extraction and standardisation, giving clinical and research teams faster access to the information needed for feasibility assessment, study planning, and real-world evidence generation.

By strengthening the data foundations that underpin oncology research, Oncoshot enables partners to accelerate cancer R&D and improve patient access to innovative treatments.

Visit www.oncoshot.com for more information.

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia

BANGKOK, Dec. 15, 2025 /PRNewswire/ -- During the Innovate Asia Autonomous Networks (AN) Masterclass held recently, Huawei core network solution expert Michael Wang, invited by TM Forum (TMF), attended the release of the Core Network Fault Management AN Solution Package. Focused on high-stability key features, the solution package integrates TM Forum's IG1500 standards to deliver reusable autonomous network templates, signaling the beginning of commercial replication for the high-stability core network solution package.

Building the Cornerstone of Core Network Stability Across Seven Dimensions

The solution package addresses seven dimensions of core network stability assurance: high-stability deployment architecture, control plane disaster recovery (DR), user plane DR, infrastructure DR, anti-signaling surge capability, risk prediction, and service degradation recovery. Based on the Management Data Analytics Function (MDAF) defined in 3GPP TS 28.104, the solution package provides a systematic, end-to-end resilience network framework. Leveraging digital twin technology, it enables closed-loop management from risk prediction to automated optimization, significantly enhancing the network's ability to withstand extreme scenarios such as signaling storms.

A key innovation lies in signaling storm risk assessment. Through digital twin modeling, the solution package constructs a virtual network environment to predict risks and implement proactive defenses. Before a signaling storm occurs, it collects traffic statistics, node connection data, and device timing configurations, and then uses a simulation engine to generate impact models. This process allows precise evaluation of network capacity and delivers optimization recommendations, helping operators eliminate potential faults in advance.

Standardization Accelerates Industry Adoption

This AN Solution Package strictly adheres to TM Forum's IG1500 standards and integrates seamlessly with existing systems via standardized APIs. In his speech, Michael Wang highlighted that the solution package provides a standardized technical implementation template and further demonstrates its feasibility in core network stability assurance scenarios via the Catalyst project. He then cited the optimization practices of an operator in infrastructure disaster recovery. Key processes include precise identification of VIP users, rapid determination of recoverable paths, and swift generation of recovery solutions. The objective is to reduce the network recovery time for VIP users from 30 minutes to 1 minute, while maintaining a 30-minute recovery time for common users. By applying differentiated service assurance policies, this solution enhances the network experience of high-value users and effectively mitigates economic losses caused by VIP user churn.

With the release of the AN Solution Package, core network stability assurance is now officially incorporated into TM Forum's standard scenarios. Huawei's replicable and scalable paradigm for high-stability network construction equips operators with a powerful tool to enhance resilience, while also providing critical support for network evaluation monetization.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

TM Forum Releases Core Network High-Reliability AN Solution Package, Leading a New Paradigm of Autonomous Networks